Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment
Katja Weisel(Universität Hamburg), Pieter Sonneveld(Erasmus MC Cancer Institute), Niels W.C.J. van de Donk(Oncode Institute), Javier de la Rubia(Universitat de València), Meletios Α. Dimopoulos(Korea University), Frederik Lersch(Bristol-Myers Squibb (Switzerland)), Barbara Gamberi(University of Modena and Reggio Emilia), Matthew Streetly(King's College - North Carolina), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Massimo Offidani(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Frank Bridoux(Université de Poitiers), Elisabeth Kueenburg(National and Kapodistrian University of Athens), Pamela Bacon(National and Kapodistrian University of Athens), Barbara Rosettani(National and Kapodistrian University of Athens)
Cited by 0
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k